Price
No data yet.
Social Signal Score
Revenue
$204.13M+727.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Olivier Loeillot
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 2,000
- Beta
- 1.01
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 8.29
Financials
Revenue
$204.13M+727.2%Net Income
$5.01M+333.6%EBITDA
$-2.39M-141.2%Free Cash Flow
$27.67MEPS (diluted)
$0.09+200.0%Shares Outstanding (diluted)
56.66M+65.1%Operating Expenses
$91.03MCash & Debt
$810.45MReturn of Capital
$1.07MRevenue by Segment (annual)
$1.48BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $738.26M | $48.89M | $0.87 |
| 2024 | $634.44M | $-25.51M | $-0.46 |
| 2023 | $632.36M | $35.60M | $0.64 |
| 2022 | $801.54M | $185.96M | $3.35 |
| 2021 | $670.53M | $128.29M | $2.33 |
| 2020 | $366.26M | $59.93M | $1.14 |
| 2019 | $270.25M | $21.41M | $0.44 |
| 2018 | $194.03M | $16.62M | $0.38 |
| 2017 | $141.24M | $28.35M | $0.74 |
| 2016 | $104.54M | $11.68M | $0.35 |
| 2015 | $83.54M | $9.35M | $0.28 |
| 2014 | $63.55M | $8.17M | $0.25 |
| 2013 | $68.17M | $16.09M | $0.51 |
| 2012 | $62.27M | $14.16M | $0.46 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RGEN's reported EPS growth of 5.0% a year over 13 years.
- EPS in 5 years
- $1.11
- Implied price
- $19.97
- Return from $180.30
- -35.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $9.93 — -94.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -5.0% | -46.3% | -43.8% | -41.7% | -39.9% | -38.3% |
| 0.0% | -43.4% | -40.9% | -38.7% | -36.7% | -35.0% |
| 5.0% | -40.6% | -37.9% | -35.6% | -33.6% | -31.8% |
| 10.0% | -37.8% | -34.9% | -32.5% | -30.4% | -28.5% |
| 15.0% | -35.0% | -32.0% | -29.5% | -27.3% | -25.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newszacks.com·6h ago·Neutral
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Sep…
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $0.46 per share
Typical surprise +11.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.54 vs $0.45beat
- Tue, May 5$0.48 vs $0.38beat
- Tue, Feb 24$0.49 vs $0.44beat
- Tue, Oct 28$0.46 vs $0.42beat
- Tue, Jul 29$0.37 vs $0.40miss
- Tue, Apr 29$0.39 vs $0.35beat
Estimates and results for RGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RGEN officers and directors.
- Bought
- $202k
- Sold
- $13.8m
1 trade
25 trades
- Loeillot Oliviersold
- Garland Jason Ksold
- Garland Jason Ksold
- Loeillot Oliviersold
- Dawes Karen Asold
- Loeillot Oliviersold
- Bylund Jamessold
- Hunt Anthonysold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.